Source Paper
Source Paper
Man Li, Shi-chun Li, Bao-kai Dou, Ying-xiang Zou, Hao-zhen Han et al.
Acta Pharmacologica Sinica • 2020
Objective: Surgical induction of focal cerebral ischemia in mice via transient occlusion of the middle cerebral artery followed by reperfusion to test neuroprotective effects of CAG treatment
This is a Middle Cerebral Artery Occlusion (MCAO) protocol using mouse as the model organism. The procedure involves 8 procedural steps, 1 equipment items, 5 materials. Extracted from a 2020 paper published in Acta Pharmacologica Sinica.
Model and subjects
mouse • C57BL/6 • male • not specified • 23-26g
Study window
~12 hour study window | ~13.5 hours hands-on
Core workflow
Animal preparation and anesthesia • Middle cerebral artery occlusion (MCAO) • Reperfusion initiation
Primary readouts
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
Use the page like this
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Male C57BL/6 mice (23-26g) were anesthetized with inhalational halothane at 1.5% concentration
Note: Anesthesia was maintained during surgical procedure
“Male C57BL/6 mice (23–26 g, Vital River Laboratory Animal Technology Co., Ltd., Beijing, China) underwent right MCAO under inhalational anesthesia (1.5% halothane)”
Right MCAO was performed using a silicon-coated suture as previously described in references 15 and 16
Note: Occlusion was maintained for 45 minutes before reperfusion
“underwent right MCAO under inhalational anesthesia (1.5% halothane) as previously described. After 45 min, the silicon-coated suture was withdrawn”
The silicon-coated suture was withdrawn after 45 minutes of occlusion to initiate reperfusion
Note: This marks the beginning of the reperfusion phase
“After 45 min, the silicon-coated suture was withdrawn to initiate reperfusion”
CAG (purity >98%) was dissolved in DMSO and then diluted with 2% Tween 20 in PBS to achieve a final DMSO concentration of 5%
Note: CAG was prepared fresh for injection
“CAG (purity > 98%, Yuanye Biotechnology, Shanghai, China) was dissolved in DMSO and then diluted with 2% Tween 20 in PBS. The final concentration of DMSO was 5%”
Animals were randomly divided into three groups: sham, MCAO, and MCAO + CAG-treated groups
Note: Randomization was performed to ensure unbiased group assignment
“The animals were randomly divided into the sham, MCAO, and MCAO + CAG-treated groups”
CAG was injected intraperitoneally (i.p.) immediately after reperfusion at doses of 5, 10, or 20 mg/kg
Note: First injection administered right after suture withdrawal
“CAG (5, 10 or 20 mg/kg, i.p.) was injected immediately after reperfusion”
CAG was injected intraperitoneally at the same dose 12 hours after the initial injection
Note: Second dose administered at 12-hour interval
“CAG (5, 10 or 20 mg/kg, i.p.) was injected immediately after reperfusion, 12 h later”
CAG was injected twice daily for up to three days following the initial injection
Note: Continued dosing regimen to maintain therapeutic levels
“then twice daily for up to three days”
This section explains what the experiment is doing, which readouts matter, what the data artifacts usually look like, and how the analysis should flow from raw capture to reported result.
Surgical induction of focal cerebral ischemia in mice via transient occlusion of the middle cerebral artery followed by reperfusion to test neuroprotective effects of CAG treatment
Objective
Surgical induction of focal cerebral ischemia in mice via transient occlusion of the middle cerebral artery followed by reperfusion to test neuroprotective effects of CAG treatment
Subjects
From papermouse • C57BL/6 • male • not specified • 23-26g
Cohort notes
From paperObtained from Vital River Laboratory Animal Technology Co., Ltd., Beijing, China
Animal preparation and anesthesia (not specified)
Middle cerebral artery occlusion (MCAO) (45 minutes)
Reperfusion initiation (at 45 minutes post-occlusion)
CAG preparation (not specified)
Focal cerebral ischemia induction (confirmed by MCAO procedure)
From papernot specified in provided text
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Neuroprotective effects of CAG treatment (measured in subsequent analyses not detailed in this methods section)
From papernot specified in provided text
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Focal cerebral ischemia induction (confirmed by MCAO procedure)
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Neuroprotective effects of CAG treatment (measured in subsequent analyses not detailed in this methods section)
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Acquisition
Collect raw experimental outputs with enough metadata to preserve sample identity, condition, and timing.
Preprocessing / cleaning
not specified in provided text
Scoring or quantification
Quantify the primary readouts for this experiment: Focal cerebral ischemia induction (confirmed by MCAO procedure); Neuroprotective effects of CAG treatment (measured in subsequent analyses not detailed in this methods section).
Statistical comparison
Statistical method not yet structured for this page.
Reporting output
Report representative outputs alongside summary comparisons for Focal cerebral ischemia induction (confirmed by MCAO procedure), Neuroprotective effects of CAG treatment (measured in subsequent analyses not detailed in this methods section).
Source links and direct wording from the methods section for validation and deeper review.
Citation
Man Li et al. (2020). Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacologica Sinica
“”
“”
“”
“”
Direct vendor pages are linked from the protocol above. This section stays focused on the full comparison view and the prep checklist.
Gather these items before starting the experiment. Check off items as you prepare.
not specified • not specified • not specified • not mentioned
Yuanye Biotechnology, Shanghai, China • not applicable • not specified • not mentioned
not specified • not applicable • not specified • not mentioned
not specified • not applicable • not specified • not mentioned
not specified • not applicable • not specified • not mentioned
not specified • not applicable • not specified • not mentioned
2 items with ReplicateScience direct pages
Estimated: $2,499.00
Use this section as the page quality checkpoint. It keeps section navigation, evidence access, readiness, and verification meaning in one place.
Current status surfaces were computed from experiment data updated Mar 14, 2026.
Source access
Jump back into the original paper or the methods evidence section when you need exact wording, exclusions, or method-specific caveats.
This protocol has structured steps plus evidence quotes, and is ready for canonical sync.
Steps
8
Evidence Quotes
14
Protocol Items
6
Linked Products
2
Canonical Sync
Pending
What this means
The completeness score reflects how much structured protocol data is present: steps, methods evidence, listed materials, linked products, and paper provenance.
Computed from the current experiment record updated Mar 14, 2026.
Canonical Sync shows whether a ConductGraph-backed protocol is available for this experiment route right now. It is a sync-status signal, not a claim that every downstream vendor link or step detail is perfect.
Steps
8
Evidence
14
Specific Products
2/2
Canonical Sync
Pending
What this score means
The verification score reflects evidence coverage, subject detail, paper provenance, step depth, and whether linked products resolve to specific item pages instead of generic searches.
Computed from the current experiment record updated Mar 14, 2026.
A page can have structured steps and still need review when evidence is thin, product links are generic, or canonical protocol coverage is still pending.